Lee Fixel is a managing partner at Tiger Global Management. He is largely known for being one of the earliest and most influential startup investors in the Indian market with companies including Ola, Flipkart, Policybazaar and Freshdesk.
His investments returned $6 billion to Tiger Global over the past year alone, with a $1.6 billion cash dividend from Juul Labs, the electronic cigarette-maker in which Altria acquired a minority interest, as well as $3.5 billion in profits from Walmart’s purchasing Flipkart and IPO proceeds from Spotify, SurveyMonkey, Eventbrite and Tencent Music.
“Lee is a strategic thinker but also does a lot of analysis before taking a decision,” Deep Kalra, CEO of MakeMyTrip, told Fortune India. “Once he decides, he moves extremely fast. Also, if the company shows good growth and market leadership potential, Tiger tends to back it in a big way”.
After almost 13 years with the firm, Lee announced that he would be stepping down as managing partner in March 2019. He plans to focus on investments with his own money and possibly open an investment firm in the future.
“Lee has been a driving force behind the expansion of Tiger Global’s private equity investing activities in the United States and India, and he has distinguished himself as a world-class investor across multiple sectors and stages,” according to a statement by the firm, as reported by CNBC.
Along with his wife, Lauren Fixel, he founded the Lauren and Lee Fixel Family Foundation. In January 2019, the foundation donated $20 million to the University of Florida and UF Health in support of a research institute dedicated to neurological diseases. Lee is also one of the top supporters of The Michael J. Fox Foundation for Parkinson’s Disease and serves on the organisation’s board of directors.
“As people live longer, Parkinson’s disease is rapidly becoming a critical health issue, with more than a million Americans expected to be living with the disease by next year,” said Lee Fixel in a press release by the university. “We believe it is essential to invest in innovative research to develop groundbreaking treatments with the goal of curbing this debilitating illness. We hope that our gift, along with extensive efforts at the University of Florida, will cement UF Health’s position as the preeminent destination for patient care, research, and technological innovation for neurodegenerative diseases.”